BioSpectrum ASIA EDITION
the business of Bio & Health Sciences

Australia's Telix starts US trial

18 April 2022 | News

First patients Dosed with Illuccix - Telix's approved prostate cancer imaging agent



Australia's Telix Pharmaceuticals has announced first commercial doses of its prostate cancer imaging agent, Illuccix® (kit for preparation of gallium Ga-68 gozetotide injection), also known as ^{68}Ga-PSMA-11 injection.

As Illuccix rolls out nationally across the United States, physicians in Indianapolis (Indiana University School of Medicine), New York City, and Seattleare among the first to administer this new PSMA PET[2] imaging agent that can help health care professionals (HCPs) diagnose the stage and spread of disease – an important step for the optimal care of men with prostate cancer.

Illuccix is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in patients with prostate cancer with:

- suspected metastasis who are candidates for initial definitive therapy;
- suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.

Illuccix is now widely available across the United States, significantly improving patient access to PSMA PET imaging. PSMA PET imaging is emerging as a standard of care in the U.S. having been included in latest NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer.